✦ LIBER ✦

B331 Tyrosine Kinase Inhibition in MM? Efficacy of the Combination of Dasatinib/Bortezomib/Dexamethasone

✍ Scribed by de Queiroz Crusoe, E; Ocio, EM; Maiso, P; San-Segundo, L; Fernández, D; Garayoa, M; Pandiella, A; San Miguel, J

Book ID: 118629481
Publisher: CIG Media Group, LP.
Year: 2009
Tongue: English
Weight: 96 KB
Volume: 9
Category: Article
ISSN: 1557-9190
DOI: 10.1016/s1557-9190(11)70709-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of the combination of bortezomi

Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis

✍ W. Lamm; W. Willenbacher; A. Lang; N. Zojer; E. Müldür; H. Ludwig; B. Schauer-St 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 192 KB

The tyrosine kinase inhibitor dasatinib

The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo

✍ Kate Vandyke; Andrea L Dewar; Peter Diamond; Stephen Fitter; Christopher G Schul 📂 Article 📅 2010 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 423 KB

## Abstract Dasatinib is a potent tyrosine kinase inhibitor that is used to treat chronic myeloid leukemia in patients resistant or intolerant to imatinib mesylate. While designed to inhibit Abl and Src kinases, dasatinib shows multitarget effects, including inhibition of the macrophage colony‐stim

603 POSTER Effect of the SRC tyrosine ki

603 POSTER Effect of the SRC tyrosine kinase inhibitor dasatinib in combination with erlotinib and in cells with acquired resistance to erlotinib

✍ E. Haura; J. Gao; J. Li 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 56 KB

36 Improved Inhibition of Tumor Growth b

36 Improved Inhibition of Tumor Growth by the Novel Monoclonal Antibody VGX-100 Targeting VEGF-C in Combination with VEGF-Receptor Tyrosine Kinase Inhibitors

✍ Tester, A.; Phelan, D.; Gerometta, M.; Klupacs, R.; Baldwin, M.E. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 56 KB

A population-based review of the feasibi

A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease

✍ Mariano, Caroline; Bosdet, Ian; Karsan, Aly; Ionescu, Diana; Murray, Nevin; Lask 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 609 KB